Literature DB >> 12137534

Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin.

Ethan A Merritt1, Zhongsheng Zhang, Jason C Pickens, Misol Ahn, Wim G J Hol, Erkang Fan.   

Abstract

Multivalent ligand design constitutes an attractive avenue to the inhibition of receptor recognition and other biological events mediated by oligomeric proteins with multiple binding sites. One example is the design of multivalent receptor blockers targeting members of the AB(5) bacterial toxin family. We report here the synthesis and characterization of a pentavalent inhibitor for cholera toxin and Escherichia coli heat-labile enterotoxin. This inhibitor is an advance over the symmetric pentacyclen-derived inhibitor described in our earlier work in that it presents five copies of m-nitrophenyl-alpha-D-galactoside (MNPG) rather than five copies of beta-D-galactose. The approximately 100-fold higher single-site affinity of MNPG for the toxin receptor binding site relative to galactose is found to yield a proportionate increase in the affinity and IC50 measured for the respective pentavalent constructs. We show by dynamic light scattering that inhibition of receptor binding by the pentavalent inhibitor is due to 1:1 inhibitor:toxin association rather than to inhibitor-mediated aggregation. This 1:1 association is in complete agreement with a 1.46 A resolution crystal structure of the pentavalent inhibitor:toxin complex, which shows that the favorable single-site binding interactions of MNPG are retained by the five arms of the 5256 Da pentavalent MNPG-based inhibitor and that the initial segment of the linking groups interacts with the surface of the toxin B pentamer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12137534     DOI: 10.1021/ja0202560

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  23 in total

1.  Rigid multivalent scaffolds based on adamantane.

Authors:  Khaled Nasr; Nadine Pannier; John V Frangioni; Wolfgang Maison
Journal:  J Org Chem       Date:  2008-01-08       Impact factor: 4.354

Review 2.  Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.

Authors:  Adrienne W Paton; Renato Morona; James C Paton
Journal:  Bioeng Bugs       Date:  2009-11-17

Review 3.  Obstructing toxin pathways by targeted pore blockage.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Chem Rev       Date:  2012-10-11       Impact factor: 60.622

4.  Binding of Clostridium botulinum C3 exoenzyme to intact cells.

Authors:  Astrid Rohrbeck; Leonie von Elsner; Sandra Hagemann; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-02       Impact factor: 3.000

Review 5.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

Review 6.  Multivalent Inhibitors of Channel-Forming Bacterial Toxins.

Authors:  Goli Yamini; Ekaterina M Nestorovich
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

7.  Oligovalent amyloid-binding agents reduce SEVI-mediated enhancement of HIV-1 infection.

Authors:  Christina C Capule; Caitlin Brown; Joanna S Olsen; Stephen Dewhurst; Jerry Yang
Journal:  J Am Chem Soc       Date:  2012-01-03       Impact factor: 15.419

8.  Architecture Effects on the Binding of Cholera Toxin by Helical Glycopolypeptides.

Authors:  Shuang Liu; Kristi L Kiick
Journal:  Macromolecules       Date:  2008-02-12       Impact factor: 5.985

9.  Selective toxin sequestrants for the treatment of bacterial infections.

Authors:  Levi S Simpson; Lyle Burdine; Amal K Dutta; Andrew P Feranchak; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2009-04-29       Impact factor: 15.419

Review 10.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.